NAYA Oncology is focused on the clinical development and strategic acquisition of first & best-in-class clinical-stage therapeutics for the treatment of cancer.

We leverage the impact of new drug modalities, novel targets, and AI-powered translational medicine to achieve breakthrough outcomes for patients.

Our initial pipeline includes 2 novel Flex-NK™ Bispecific Antibodies acquired from Cytovia Therapeutics:
















Both products have been validated at major oncology meetings, including ASH, AACR, SITC, ESMO, and ASGCT, and are on track for clinical trial initiation starting early 2024, with value-creating readouts in 2024-2025.

Clinical development has been designed by our scientific advisory board of leading liver cancer & multiple myeloma experts to allow for early inflection points and accelerated development based on early data.